Related Experiment Video

Updated: May 30, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions

Daniel Y C Heng1, Christian Kollmannsberger, Kim N Chi

  • 1BC Cancer Agency, 600 West 12 Avenue, Vancouver, British Columbia, V5Z 4E6, Canada.

Therapeutic Advances in Medical Oncology
|July 27, 2011
PubMed

Insights

Targeted therapies targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have transformed metastatic renal cell carcinoma (RCC) treatment, largely replacing immunotherapy. New agents and combination strategies are under investigation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (RCC) treatment has evolved significantly.
  • Vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways are key targets in RCC therapy.
  • Targeted therapies have largely replaced immunotherapy as the standard of care for advanced RCC.

Purpose of the Study:

  • To review the current landscape of targeted therapies for metastatic RCC.
  • To discuss emerging targeted agents and treatment strategies.
  • To highlight ongoing clinical trials exploring new therapeutic approaches.

Main Methods:

  • Review of phase III randomized trials.
  • Analysis of approved anti-VEGF and mTOR-targeted agents.
  • Discussion of novel targeted therapies and inhibitors in development.
  • Examination of ongoing clinical trials for combination and sequential therapies.

Main Results:

  • Anti-VEGF agents (sunitinib, sorafenib, bevacizumab) and mTOR inhibitors (temsirolimus, everolimus) are established treatments.
  • New targeted therapies including axitinib, pazopanib, and c-met inhibitors show promise.
  • Sequential and combination targeted therapies are under investigation for advanced disease.

Conclusions:

  • Targeted therapies targeting VEGF and mTOR pathways have revolutionized metastatic RCC treatment.
  • Ongoing research focuses on expanding treatment options with novel agents and strategies.
  • Adjuvant and neoadjuvant approaches around nephrectomy are also being explored.
Keywords:
adjuvantcombination therapymammalian target of rapamycinneo-adjuvantnonclear cell histologiesrenal cell carcinomavascular endothelial growth factor

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...